December was a topsy turvy month for crypto, but growing stablecoin reserves could hint at a fresh rally as Trump's ...

The co-developer of a US-approved drug, Professor Andrew Wilks has formed Synthesis Bioventures to sniff out more winners.

Aldoro led resources stock gains in December on strong niobium sampling results at its Kameelburg project in Namibia.

Settling on a name for a mineral deposit isn’t quite as important as naming a child but it’s clear some are more creative ...

The high-risk strategies employed by aggressive growth funds have paid off in a bumper year for members. Analysis by ...

Aussie shares moved up on Thursday. Energy stocks led, Lendlease dipped, Brainchip soared, and the AUD hit a two-year low.

The Australian sharemarket surged in 2024, adding nearly $200bn to the value of the benchmark ASX 200 index, despite a ...

The ASX is on the up on Thursday, while Lendlease sells UK unit, Brainchip rallies again, the Aussie dollar drops and home ...

Tony Rovira was at the reins when Azure’s world-class Azure deposit was taken over by Hancock and SQM in a $1.7bn deal.

Donald Trump's re-election as US president adds to uncertainty for the year ahead, according to analysts who have given their ...

New data shows the 40 key ASX biotechs gained an average 50% in 2024 - but not all of them joined the winner's circle.

In this episode of the Unicorns podcast, Justin talks with Mark Schneider, Chief Nuclear Officer at UBH Group.